HEPH Hollis-Eden Pharmaceuticals (MM)

The Wall Street Transcript has published an in-depth interview with Richard Hollis, Chairman, President and CEO of Hollis-Eden Pharmaceuticals (NASDAQ:HEPH) in which he talks at length about the Company. The entire 2,500 word interview is available free online at http://www.twst.com/ceos.htm Hollis-Eden Pharmaceuticals, Inc. is a world leader in the development of a proprietary class of adrenal steroid hormones as novel pharmaceuticals for human health. The Company�s clinical drug development candidates include TRIOLEX� (HE3286), a next-generation compound currently in clinical trials for the treatment of type 2 diabetes, ulcerative colitis and rheumatoid arthritis, and APOPTONE� (HE3235), a next-generation compound in a clinical trial for late-stage prostate cancer. In addition to these clinical development candidates, Hollis-Eden has an active research program that is generating additional new clinical leads that are being further evaluated in preclinical models of a number of different diseases. When asked about the company�s product candidates Mr. Hollis stated, �We�ve discovered novel innovative first-in-class drug candidates that are based on endogenous adrenal steroid hormones, and since these are nature�s products, they are basically designed to perform certain functions that can be used in treating human diseases. So I believe the probability of translation from pre-clinical animal models to humans should be very high because the products originate out of our own metabolome.� Regarding the company's clinical studies Mr. Hollis stated, �Clinical endpoint data is due over the next three to six months and any inflection points that show that our technology is safe and efficacious in those indications should also allow us to expand into several other additional indications, which would increase our economic opportunity even more.� The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call 800/246-7673.